Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dr. Felgenträger & Co. Ökoplan was a German biotechnology and pharmaceutical company based in the BioPharmaPark Dessau-Roßlau. The company specialized in the development and manufacturing of vaccines, diagnostics, and environmental hygiene products, with a particular expertise in oral vaccination for wildlife. It gained international prominence for its production of the Lysvulpen vaccine, which was instrumental in the elimination of rabies in fox populations across Europe. In 2011, the company was formally merged into IDT Biologika, a major global contract development and manufacturing organization (CDMO). Today, its legacy operations continue as part of IDT Biologika's animal health and vaccine production divisions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dr. Felgenträger & Co. Ökoplan.